Publicaciones (75) Publicaciones de María Esperanza Rodríguez Ruiz

2024

  1. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

    Molecular Cancer, Vol. 23, Núm. 1

  2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  3. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  4. Radiotherapy protocols for mouse cancer model

    Methods in Cell Biology (Academic Press Inc.), pp. 99-113

2023

  1. A simple method to assess clonogenic survival of irradiated cancer cells

    Methods in Cell Biology, Vol. 174, pp. 127-136

  2. Flow cytometry-assisted quantification of immune cells infiltrating irradiated tumors in mice

    Methods in Cell Biology, Vol. 174, pp. 1-16

  3. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  4. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  5. Methods to assess radiation induced abscopal responses in mice

    Methods in Cell Biology (Academic Press Inc.), pp. 81-92

  6. PSA reactivity in extracellular microvesicles to commercial immunoassays

    Clinica Chimica Acta, Vol. 543

  7. The Lymphatic Endothelium in the Context of Radioimmuno-Oncology

    Cancers, Vol. 15, Núm. 1

2022

  1. Assessment of hypoxia by pimonidazole staining following radiotherapy

    Methods in Cell Biology (Academic Press Inc.), pp. 179-189

  2. Charting roadmaps towards novel and safe synergistic immunotherapy combinations

    Nature Cancer, Vol. 3, Núm. 6, pp. 665-680

  3. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1248-1265

  4. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

  5. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

    Theranostics, Vol. 12, Núm. 3, pp. 1373-1387

  6. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  2. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

  3. Considerations for treatment duration in responders to immune checkpoint inhibitors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3